Skip to content

To assess tear film changes after intense pulse light therapy in Iranian patients with meibomian gland dysfunction.

To assess the effect of intense pulse light therapy in Iranian patients with meibomian gland dysfunction.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190507043503N1
Enrollment
100
Registered
2019-07-13
Start date
2019-05-22
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian gland dysfunction. Evaporative dry eye- dry eye syndrome

Interventions

Intervention 1: Intervention group: 50 patients with meibomian gland dysfunction will undergo 3 sessions of intense pulse light therapy. Meanwhile routine dry eye therapy consisting using artificial t

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with a diagnosis of meibomian gland dysfunction according to international diagnostic criteria Patients who have ethical consent for participating in the study Patients who have the history of at least 2 months taking current medications for meibomian gland dysfunction.

Exclusion criteria

Exclusion criteria: Having any ocular or systemic disease Having any history of ophthalmic surgeries Taking medications with photo sensitivity side effects Contact lens wearers Having nevus or tattoos in palpebral and peri orbital region

Design outcomes

Primary

MeasureTime frame
OSDI score: this ocular surface index questionnaire consists of 12 question and assesses the severity of dry eye. Timepoint: Baseline, day 14, day 45, day 75. Method of measurement: sum of score of questionnaire which has been filled by the patients.;TBUT : tear break up time. Timepoint: Baseline, day 14, day 45, day 75. Method of measurement: keratograph, slit lamp.;Osmolarity: tear film density. Timepoint: baseline, day 75. Method of measurement: tear lab device.

Secondary

MeasureTime frame
Meibomian gland drop out which is graded from 0 to 3. Timepoint: baseline, day 14, day 45, day 75. Method of measurement: keratograph device.;PSQI: Pittsburgh sleep quality index. Timepoint: BASELINE, DAY 75. Method of measurement: Sum of score of questionnaire which has been filed by the patients.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Hassanzadeh

Mashhad University of Medical Sciences

samip2005@yahoo.com+98 915 158 1572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026